Codexis Inc. (CDXS), an enzyme engineering company, is setting its sights on achieving profitability by the end of 2026, driven by the growing demand for its innovative enzymatic solutions.
The company uses its proprietary CodeEvolver directed evolution technology platform to develop optimized enzymes that are used by some of the world's largest pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It has collaborations and agreements with GSK, Merck, Novartis, Roche, Aldevron, Nestlé Health Science, Crosswalk Therapeutics and Alphazyme.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com